How to buy Virios Therapeutics stock (Virios Therapeutics)

Virios Therapeutics is a biotechnology business based in the US. Virios Therapeutics shares (VIRI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.74 – the same closing value as a week prior. Virios Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Virios Therapeutics Llc stock

Buy Virios Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Virios Therapeutics stock price (NASDAQ: VIRI)

Use our graph to track the performance of VIRI stocks over time.

Virios Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-22.

Latest market close	$2.74
52-week range	$1.62 - $23.50
50-day moving average more info button	$4.51
200-day moving average more info button	$7.69
Wall St. target price	$3.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-5.75

Is it a good time to buy Virios Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Virios Therapeutics price performance over time

Historical closes compared with the close of $2.74 from 2024-12-10

1 week (2024-12-17)	N/A
1 month (2024-11-27)	5.38%
3 months (2024-09-27)	1,365.24%
6 months (2024-06-28)	1,174.42%

1 year (2023-12-28)	371.84%
2 years (2022-12-28)	-54.10%
3 years (2021-12-28)	129
5 years (2019-12-24)	N/A

Virios Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-67.76%
Return on equity TTM	-119.56%
Profit margin	0%
Book value	$2.82
Market Capitalization more info button	$206,501

TTM: trailing 12 months

Virios Therapeutics share dividends

We're not expecting Virios Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Gilead Sciences (GILD.US) (3.33% forward annual dividend yield)

Have Virios Therapeutics's shares ever split?

Virios Therapeutics's shares were split on a 1:25 basis on 8 October 2024 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Virios Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Virios Therapeutics shares which in turn could have impacted Virios Therapeutics's share price.

Virios Therapeutics share price volatility

Over the last 12 months, Virios Therapeutics's shares have ranged in value from as little as $1.62 up to $23.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Virios Therapeutics's is 1.582. This would suggest that Virios Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Virios Therapeutics's beta into context you can compare it against those of similar companies.

• BioCryst Pharmaceuticals (BCRX.US): 1.887
• Gilead Sciences (GILD.US): 0.192
• Inovio Pharmaceuticals (INO.US): 0.833

Virios Therapeutics overview

Virios Therapeutics, Inc. , a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Frequently asked questions

What percentage of Virios Therapeutics is owned by insiders or institutions?
Currently 6.738% of Virios Therapeutics shares are held by insiders and 3.604% by institutions. How many people work for Virios Therapeutics?
Latest data suggests 4 work at Virios Therapeutics. When does the fiscal year end for Virios Therapeutics?
Virios Therapeutics's fiscal year ends in December. Where is Virios Therapeutics based?
Virios Therapeutics's address is: 44 Milton Avenue, Alpharetta, GA, United States, 30009 What is Virios Therapeutics's ISIN number?
Virios Therapeutics's international securities identification number is: US92829J1043